Family Management Corp grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 14.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,336 shares of the company’s stock after buying an additional 4,035 shares during the quarter. Johnson & Johnson accounts for about 1.7% of Family Management Corp’s investment portfolio, making the stock its 13th biggest position. Family Management Corp’s holdings in Johnson & Johnson were worth $4,364,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtus ETF Advisers LLC purchased a new stake in Johnson & Johnson during the second quarter worth $25,000. Krane Funds Advisors LLC purchased a new stake in Johnson & Johnson during the second quarter worth $26,000. Crewe Advisors LLC lifted its holdings in Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after buying an additional 196 shares during the period. Permanens Capital L.P. lifted its holdings in Johnson & Johnson by 50.0% during the second quarter. Permanens Capital L.P. now owns 300 shares of the company’s stock worth $42,000 after buying an additional 100 shares during the period. Finally, Thor Advisors LLC purchased a new stake in Johnson & Johnson during the first quarter worth $69,000. 72.01% of the stock is currently owned by hedge funds and other institutional investors.
Shares of JNJ opened at $131.46 on Friday. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a fifty day moving average price of $130.02 and a 200-day moving average price of $135.75. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The firm has a market cap of $342.22 billion, a PE ratio of 16.07, a P/E/G ratio of 2.19 and a beta of 0.68.
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a dividend yield of 2.89%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
A number of research firms have weighed in on JNJ. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, August 27th. Bank of America restated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 16th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price for the company. in a report on Thursday, July 18th. Finally, Morgan Stanley restated an “equal weight” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 27th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $150.60.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: What is the Dividend Aristocrat Index?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.